About Tarus Therapeutics
Tarus Therapeutics is a company based in New York (United States) founded in 2019 by Donald R Dye and Peter Molloy was acquired by Portage Biotech in July 2022. Tarus Therapeutics offers products and services including iNKT Platform, Adenosine Platform, and Other Programs.
- Headquarter New York, United States
- Founders Donald R Dye, Peter Molloy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Portage Biotech Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Portage Biotech
(Jul 06, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tarus Therapeutics
Tarus Therapeutics offers a comprehensive portfolio of products and services, including iNKT Platform, Adenosine Platform, and Other Programs.
Develops therapies targeting cancer resistance pathways
Focuses on immuno-oncology drug development for cancer
Advances additional novel assets in oncology research
Funding Insights of Tarus Therapeutics
Detailed funding history for Tarus Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Tarus Therapeutics
Tarus Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Portage Biotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics based on Cell Permeable Peptide Platform
|
Locked | Locked | Locked |
Investor details for Tarus Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tarus Therapeutics
Investment portfolio details for Tarus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tarus Therapeutics
Detailed financials for Tarus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tarus Therapeutics Comparisons
Peer comparison for Tarus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tarus Therapeutics
Detailed competitors of Tarus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tarus Therapeutics
Complete news archive for Tarus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tarus Therapeutics
Tarus Therapeutics was founded in 2019.
Tarus Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Tarus Therapeutics was founded in 2019 in New York, United States. Therapeutics for cancer treatment are developed by the company within the biotechnology sector. Lead candidates are focused on the immunosuppressive adenosine pathway in the tumor microenvironment. These candidates are aimed at addressing resistant cancers through operations centered on drug development. The companys activities are based in the United States.
Tarus Therapeutics offers iNKT Platform, Adenosine Platform, and Other Programs.
Tarus Therapeutics has 1 investor. Key investors include Portage Biotech.